The present invention relates to an ocular composition comprising a) at least 0.1% w/w of a therapeutic agent; b) 5 to 95% w/w of a photopolymerizable composition comprising 3 to 70% w/w of one or more compounds of formula I: (I) wherein R.sub.1 is hydrogen or a linear or branched C.sub.1-C.sub.3 alkyl; R.sub.2 is an acrylate or methacrylate group; n is 2 or 3 and m is equal or greater than 1, the weight percentage of the one or more compounds of formula I being based on the total weight of the photopolymerizable composition; c) 0.1 to 40% w/w of a biodegradable polymer selected from the group consisting of lactide/glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide/caprolactone copolymer,

The present invention relates to an ocular composition comprising a) at least 0.1% w/w of a therapeutic agent; b) 5 to 95% w/w of a photopolymerizable composition comprising 3 to 70% w/w of one or more compounds of formula I: (I) wherein R.sub.1 is hydrogen or a linear or branched C.sub.1-C.sub.3 alkyl; R.sub.2 is an acrylate or methacrylate group; n is 2 or 3 and m is equal or greater than 1, the weight percentage of the one or more compounds of formula I being based on the total weight of the photopolymerizable composition; c) 0.1 to 40% w/w of a biodegradable polymer selected from the group consisting of lactide/glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide/caprolactone copolymer,

Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.

Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.

The invention provides a highly versatile system to promote vascularization in ischemic tissue. The system is composed of a fully defined, customizable hydrogel loaded with a potent cocktail of proangiogenic growth factors. The hydrogel's mechanical, degradation, and factor release behavior can be tailored to the specifications of any given target tissue or ischemic disease state. The growth factor cocktail can be optimized for maximal vessel density or size to meet the perfusion specifications required by the tissue. The embodiments of the disclosure concern methods and compositions of the system, with examples of preparation for both injectable and implantable delivery modes.

The invention provides a highly versatile system to promote vascularization in ischemic tissue. The system is composed of a fully defined, customizable hydrogel loaded with a potent cocktail of proangiogenic growth factors. The hydrogel's mechanical, degradation, and factor release behavior can be tailored to the specifications of any given target tissue or ischemic disease state. The growth factor cocktail can be optimized for maximal vessel density or size to meet the perfusion specifications required by the tissue. The embodiments of the disclosure concern methods and compositions of the system, with examples of preparation for both injectable and implantable delivery modes.

The present disclosure relates to combinations of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide having phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, and methods of preparing the conjugates.